Clinical Trials Browser

Phase 2 × Recruiting × Lymphoma, Large B-Cell, Diffuse × Clear all

NCT03418038 2026-03-18

Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia

Phase 2 Recruiting

LymphoidOther hematologic neoplasm

Hodgkin Disease, Lymphoma, Leukemia, Myelomonocytic, Chronic, Lymphoma, Large B-Cell, Diffuse

NCT06500273 2026-03-18

ALPHA3

Phase 2 Recruiting

Lymphoma, Large B-Cell, Diffuse, Neoplasm, Residual

NCT06784726 2026-03-13

Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T

Phase 2 Recruiting

Lymphoma, Large B-Cell, Diffuse

NCT05800366 2026-03-05

A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma

Phase 2 Recruiting

Lymphoma, Lymphoma, Large B-Cell, Diffuse

NCT07042438 2026-03-05

Fecal Microbiome Transplant to Remodel Intestinal Microbiota for Patients With Relapsed or Refractory Lymphoma With Exposure to High-Risk Antibiotics Who Are Receiving Chimeric Antigen Receptor T Cells

Phase 2 Recruiting

Lymphoma, Large B-Cell, Diffuse

NCT07451652 2026-03-05

Low Dose Epcoritamab Plus GemOx in R/R DLBCL

Phase 2 Recruiting

Lymphoma, Large B-Cell, Diffuse

NCT05283720 2026-03-03

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

Phase 2 Recruiting

LymphoidOther hematologic neoplasm

Leukemia, Hairy Cell, Lymphoma, Non-Hodgkin, Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT06486051 2026-03-03

ENABLE-2

Phase 2 Recruiting

Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT06806033 2026-03-02

A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma

Phase 2 Recruiting

Cytokine Release Syndrome, Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT04195633 2026-02-27

Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies

Phase 2 Recruiting

LymphoidMyeloidOther hematologic neoplasm

Burkitt Lymphoma, Hodgkin Disease, Lymphoma, Follicular, Myelodysplastic Syndromes, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Biphenotypic, Acute, Leukemia, Prolymphocytic, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05757219 2026-02-27

Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy

Phase 2 Recruiting

Lymphoma, Large B-Cell, Diffuse

NCT04002947 2026-02-20

Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma

Phase 2 Recruiting

Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT07397832 2026-02-09

CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCL

Phase 2 Recruiting

Lymphoma, Large B-Cell, Diffuse

NCT05633615 2026-02-02

Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Phase 2 Recruiting

Lymphoma, Large B-Cell, Diffuse

NCT07371923 2026-01-28

Application of Zanubrutinib-based Combination Regimens in the Treatment of Newly-diagnosed Diffuse Large B-cell Lymphoma

Phase 2 Recruiting

Lymphoma, Large B-Cell, Diffuse

NCT06846463 2026-01-23

Zanubrutinib in Patients With DLBCL and MYD88 or NOTCH1 Mutation or CD5+

Phase 2 Recruiting

LymphoidSarcoma

Lymphoma, Large B-Cell, Diffuse, Dendritic Cell Sarcoma, Interdigitating

NCT07097363 2026-01-15

Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma

Phase 2 Recruiting

Burkitt Lymphoma, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT05952024 2025-12-22

ACRUE

Phase 2 Recruiting

Lymphoma, Large B-Cell, Diffuse

NCT06736613 2025-12-18

A Study of Circulating Tumor DNA (ctDNA) Testing for People With B-Cell Lymphoma

Phase 2 Recruiting

LymphoidSarcoma

Lymphoma, Large B-Cell, Diffuse, Dendritic Cell Sarcoma, Interdigitating

NCT07062627 2025-12-17

Anbalcabtagene Autoleucel in Relapsed/Refractory CNS Lymphoma

Phase 2 Recruiting

Lymphoma, Lymphoma, Large B-Cell, Diffuse

NCT07189065 2025-12-16

A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma

Phase 2 Recruiting

Lymphoma, Large B-Cell, Diffuse

NCT06803693 2025-12-08

Efficacy and Safety of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL

Phase 2 Recruiting

Lymphoma, Large B-Cell, Diffuse

NCT07254754 2025-11-28

LATE-R-GEL-23

Phase 2 Recruiting

Lymphoma, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT06765317 2025-11-26

A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma

Phase 2 Recruiting

Lymphoma, Large B-Cell, Diffuse

NCT05821088 2025-11-20

Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma

Phase 2 Recruiting

Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT06550141 2025-11-14

Emapalumab Prevention of CAR-T Cell Associated Toxicities

Phase 2 Recruiting

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT06687772 2025-10-27

CNS-PHLAT

Phase 2 Recruiting

Lymphoma, Large B-Cell, Diffuse

NCT05890352 2025-10-20

Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment

Phase 2 Recruiting

Lymphoma, Large B-Cell, Diffuse

NCT06828991 2025-10-20

GOLD

Phase 2 Recruiting

Lymphoma, Large B-Cell, Diffuse, Neoplasm, Residual

NCT05453396 2025-10-16

Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies

Phase 2 Recruiting

Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT05672251 2025-10-06

Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Phase 2 Recruiting

Lymphoma, Large B-Cell, Diffuse

NCT02227251 2025-10-01

Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Phase 2 Recruiting

244 enrolled 2 FDA

Lymphoma, Large B-Cell, Diffuse

NCT06854159 2025-09-29

Odronextamab for the Treatment of Relapsed and Refractory Diffuse Large B-cell Lymphoma Before and After Chimeric Antigen Receptor T-cell Therapy

Phase 2 Recruiting

Lymphoma, Large B-Cell, Diffuse

NCT06664411 2025-08-19

Pola-ZR2P in Previously Untreated DLBCL

Phase 2 Recruiting

Lymphoma, Large B-Cell, Diffuse

NCT07078500 2025-08-19

Orelabrutinib Combined With Pola-R-CHP Regimen for the Treatment of Untreated Non-GCB Diffuse Large B-Cell Lymphoma

Phase 2 Recruiting

Lymphoma, Large B-Cell, Diffuse

NCT07126236 2025-08-17

REPIFIR

Phase 2 Recruiting

Lymphoma, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT02393157 2025-08-08

O-ICE

Phase 2 Recruiting

Burkitt Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT06651853 2025-07-23

Large Fraction Radiation Therapy Combined With Lenalidomide, and Glofitamab in Refractory Relapsed DLBCL

Phase 2 Recruiting

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT06682130 2025-07-14

ASCT DLBCL

Phase 2 Recruiting

Lymphoma, Large B-Cell, Diffuse

NCT07001540 2025-06-19

Evaluation of the Efficacy and Safety of Polatuzumab Vedotin Combined With Rituximab, Gemcitabine, and Oxaliplatin (Pola-R-GemOx) as Salvage Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients Ineligible for Autologous Transplantation

Phase 2 Recruiting

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT06793410 2025-06-05

Vaccination Against Human Papillomavirus (HPV) After Allogeneic Stem Cell Transplantation

Phase 2 Recruiting

LymphoidMyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Lymphoma, Large B-Cell, Diffuse, Papillomavirus Infections

NCT06244368 2025-05-14

GVM±R in Patients With Relapsed or Refractory Aggressive NHL.

Phase 2 Recruiting

Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral

NCT04792489 2025-04-24

DALY II USA/ MB-CART2019.1 for DLBCL

Phase 2 Recruiting

Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Central Nervous System Neoplasms, Lymphoma, Mantle-Cell

NCT03936153 2025-04-10

Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Phase 2 Recruiting

Lymphoma, Large B-Cell, Diffuse

NCT06918912 2025-04-09

LORELY

Phase 2 Recruiting

Lymphoma, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT06050694 2025-04-06

GRAIL

Phase 2 Recruiting

Lymphoma, Large B-Cell, Diffuse

NCT06458439 2025-03-27

Epcoritamab-CAR T Cells for Large B-cell Lymphomas

Phase 2 Recruiting

Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT06854445 2025-03-24

Clinical Trial of TQB2825 Injection Combined With Chemotherapy in Subjects With Diffuse Large B-cell Lymphoma

Phase 2 Recruiting

Lymphoma, Large B-Cell, Diffuse

NCT06764017 2025-03-19

CHiR Therapy for Elderly DLBCL Intolerant to Chemo

Phase 2 Recruiting

Lymphoma, Large B-Cell, Diffuse

NCT06758037 2025-03-18

HiR+X

Phase 2 Recruiting

Lymphoma, Large B-Cell, Diffuse